×
About 1,753 results

ALLMedicine™ Microscopic Polyangiitis Center

Research & Reviews  556 results

EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
https://doi.org/10.1136/ard-2022-223764
Annals of the Rheumatic Diseases; Hellmich B, Sanchez-Alamo B et. al.

Mar 18th, 2023 - Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clini...

Experts share early details prescribing avacopan for ANCA-associated vasculitis
https://www.mdedge.com/rheumatology/article/261785/lupus-connective-tissue-diseases/experts-share-early-details-prescribing
Jeff Craven

Mar 14th, 2023 - When the Food and Drug Administration approved avacopan (Tavneos) as an adjunctive treatment for severe, active antineutrophil cytoplasmic autoantibody (ANCA)–associated vasculitis (AAV) in October 2021, the oral complement C5a receptor inhibitor.

Diffuse Proliferative Glomerulonephritis
http://emedicine.medscape.com/article/239646-overview

Mar 9th, 2023 - Practice Essentials Diffuse proliferative glomerulonephritis (DPGN) is a term used to describe a distinct histologic form of glomerulonephritis common to various types of systemic inflammatory diseases, including autoimmune disorders (eg, systemic...

Diffuse Proliferative Glomerulonephritis
https://emedicine.medscape.com/article/239646-print

Mar 9th, 2023 - Practice Essentials Diffuse proliferative glomerulonephritis (DPGN) is a term used to describe a distinct histologic form of glomerulonephritis common to various types of systemic inflammatory diseases, including autoimmune disorders (eg, systemic...

Diffuse Proliferative Glomerulonephritis
https://emedicine.medscape.com/article/239646-overview

Mar 9th, 2023 - Practice Essentials Diffuse proliferative glomerulonephritis (DPGN) is a term used to describe a distinct histologic form of glomerulonephritis common to various types of systemic inflammatory diseases, including autoimmune disorders (eg, systemic...

see more →

Guidelines  2 results

2022 American College of Rheumatology/European Alliance of Associations for Rheumatolog...
https://doi.org/10.1002/art.41983
Arthritis & Rheumatology (Hoboken, N.J.); Suppiah R, Robson JC et. al.

Feb 3rd, 2022 - To develop and validate classification criteria for microscopic polyangiitis (MPA). Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate items ...

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Managemen...
https://doi.org/10.1002/art.41773
Arthritis & Rheumatology (Hoboken, N.J.); Chung SA, Langford CA et. al.

Jul 9th, 2021 - To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  37 results

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
https://clinicaltrials.gov/ct2/show/NCT02257866

Feb 8th, 2023 - The purpose of this protocol is to study the natural history of idiopathic systemic vasculitis in children and adults. The idiopathic vasculitides are a group of rare, systemic diseases involving inflammation of arteries and other tissue with resu...

Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
https://clinicaltrials.gov/ct2/show/NCT05716334

Feb 8th, 2023 - Background. Rituximab (RTX), a B-cell depleting therapy, has comparable efficacy to cyclophosphamide for induction of remission in severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) and superior efficacy to azathiopri...

Biocollection of Patients With ANCA Associated Vasculitis
https://clinicaltrials.gov/ct2/show/NCT05364892

Oct 31st, 2022 - Vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA) is a group of rare and severe autoimmune diseases, encompassing several entities: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (PMA), and eosinophilic granu...

Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis
https://clinicaltrials.gov/ct2/show/NCT03920722

Sep 27th, 2022 - Microscopic polyangiitis (MPA), is a small-sized vessel necrotizing vasculitis associated with anti-neutrophils cytoplasmic antibody (ANCA). Treatment of ANCA associated vasculitis (AAV) was previously based on glucocorticoids (GC) and cyclophosph...

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
https://clinicaltrials.gov/ct2/show/NCT03895801

Aug 25th, 2022 - Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a group of potentially life-threatening autoimmune diseases. Preclinical data demonstrate that primed neutrophils are activated by anti-neutrophil cytoplasmic antibody (ANCA) and ...

see more →

News  94 results

Experts share early details prescribing avacopan for ANCA-associated vasculitis
https://www.mdedge.com/rheumatology/article/261785/lupus-connective-tissue-diseases/experts-share-early-details-prescribing
Jeff Craven

Mar 14th, 2023 - When the Food and Drug Administration approved avacopan (Tavneos) as an adjunctive treatment for severe, active antineutrophil cytoplasmic autoantibody (ANCA)–associated vasculitis (AAV) in October 2021, the oral complement C5a receptor inhibitor.

Clinical Signs Differ Between Kids and Adults With Vasculitis
https://www.medscape.com/viewarticle/983971

Nov 12th, 2022 - Researchers have found a link between age of diagnosis and various clinical characteristics and outcomes in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The findings, presented Saturday at the American Coll...

Updated EULAR recommendations for AAV include new drugs, practices
https://www.mdedge.com/rheumatology/article/255157/lupus-connective-tissue-diseases/updated-eular-recommendations-aav
Sara Freeman

Jun 2nd, 2022 - The European Alliance of Associations for Rheumatology has updated its recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). The 2022 revision – which was unveiled at the annual European Cong.

Plasma Exchange Works for ANCA-Associated Vasculitis
https://www.medscape.com/viewarticle/969671

Mar 8th, 2022 - NEW YORK (Reuters Health) - Plasma exchange can be an effective treatment for anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), according to an updated systematic review and meta-analysis. Granulomatosis with polyangiitis and ...

Don't Expect Much From COVID Vax in This Patient Group
https://www.medpagetoday.com/rheumatology/generalrheumatology/96649

Jan 13th, 2022 - Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance t...

see more →

Patient Education  6 results see all →